Trevena Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain Nov 14, 2012 9:00 am EST
Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting Sep 7, 2012 9:00 am EDT
Trevena Angiotensin Receptor Biased Ligand Promotes Cell Survival During Acute Cardiac Injury Sep 4, 2012 1:30 pm EDT
Trevena Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered with Furosemide in Dog Heart Failure Model Sep 4, 2012 1:00 pm EDT
Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules May 2, 2012 8:30 am EDT
Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain Feb 13, 2012 8:30 am EST
Trevena Receives Research Funding for Parkinson’s Disease from The Michael J. Fox Foundation Dec 19, 2011 8:30 am EST
Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations Sep 12, 2011 9:00 am EDT
Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug Aug 18, 2011 4:51 pm EDT